• 29 COPD trials. Criteria: ≥500 patients and ≥ 24-week study duration (mostly 1 year) • 80 study arms, 198-3,006 patients each → 43,472 patients.
METHODS
• Chronic obstructive pulmonary disease (COPD) is characterized by chronically poor airflow that worsens over time and leads to exacerbations.
• Severity of disease is often categorized into GOLD stages using thresholds of %FEV1, which is the percentage of normal FEV1, given body size, age, race and sex.
• The natural progression of disease results in decreased %FEV1 over time.
• Pharmacologic interventions may decrease exacerbations and slow FEV1 decline • The change observed for a given intervention may vary based on the exact nature of the clinical trial.
• Pharmacoeconomic models are often used to combine disease characteristics with treatment effects to estimate outcomes. • Pharmacometric model-based meta-analysis (PMBMA) is a type of meta-regression which employs non-linear models estimated on trial-level data to relate patient and trial characteristics, dosing, surrogate markers, and outcomes effects of treatment.
OBJECTIVE
• The study objective was to utilize PMBMA results within a health economic microsimulation model (HEMM) of COPD to better predict HE outcomes based on trial design. 
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INCORPORATING A PHARMACOMETRIC MODEL-BASED META-ANALYSIS INTO A HEALTH ECONOMIC MICROSIMULATION MODEL OF COPD
MARKOV MICROSIMULATION MODEL
• Estimated monthly changes in the key disease severity metrics of COPD (FEV1 and exacerbations).
• Compared a hypothetical drug to baseline medication.
• PMBMA predicted baseline exacerbation rate in 1,097 trial patients.
• Hypothetical drug effect (FEV1increase), modified exacerbation rate in the drug arm.
• Tracker variables stored monthly FEV1 changes for individual patients.
• FEV1 rate of decline varied by patient and by month allowing for stochastic improvements.
Model Assumptions
• 12 one-month cycles, constructed in TreeAge Pro.
• Effectiveness was measured as quality-adjusted life-years (QALYs).
• 500 Markov microsimulations were performed for each scenario (6 scenarios, 2 severity subgroups). • The synergistic aspects of PMBMA and HEMM are highlighted in this hypothetical example.
• We illustrate how exacerbation and QALY outcomes can vary significantly based on trial design assumptions.
• PMBMA use allowed placebo exacerbation rate predictions for patient subgroups.
• Microsimulation of individual patients allowed severity subgroup analysis, illustrating differential baseline exacerbations and expected drug effects; an improvement upon 'average patient' cohort models.
• Markov microsimulation modeling allows the finer predictions of PMBMA to inform parameters while individual simulations allow advantages of model memory.
• While cost-effectiveness ratios are not shown here, the economic results showed a degree of variation similar to the QALY results.
• The model illustrated here has utility in:
1. Predicting health economic outcomes given a target product profile. 2. Understanding implications of trial design and trial population decisions.
• The modeled drug effect of decreased exacerbations is related solely to an increase in FEV1. This assumption is a limitation of this model. The hypothetical drug may show effectiveness through other mechanisms. Similarly, FEV1 changes may not necessarily be associated with changes in exacerbations.
